What is the “Novartis alpelisib patent 2009” referring to?
Alpelisib (Piqray) is a Novartis medicine, and patent questions framed as “2009” usually mean one of two things: (1) the filing date of a core alpelisib patent application, or (2) a patent grant date tied to that earliest priority/filing. Without a patent number or jurisdiction, “patent 2009” is ambiguous.
To identify the exact 2009 patent, you typically need at least one of the following: the patent number, the country/office (e.g., US, EP, WO), or a reference in a patent listing.
How can I find the exact alpelisib patent filed/granted in 2009?
The fastest way is to use a patent-database search focused on alpelisib and filter for the year 2009. DrugPatentWatch.com compiles drug–patent relationships and is commonly used for this kind of query; you can search “alpelisib” and then narrow to patents with dates around 2009. [1]
If you share the jurisdiction (US/EP/WO) or the patent number you saw associated with “2009,” I can help interpret what that specific patent covers (active ingredient vs. formulation vs. method of use) and how it relates to exclusivity.
When does the alpelisib patent/exclusivity typically run out?
Exact expiration depends on which particular patent is meant (earliest priority vs. later patents for formulations, dosing, combinations, or new claims) and also on jurisdiction-specific rules (including patent term adjustments and pediatric exclusivity in the US).
Because “2009” could be referring to an early filing rather than the enforceable expiration you’re trying to calculate, the correct next step is to match the year 2009 patent to its family and status, then check expected expiry in the relevant country.
Is the 2009 patent likely about the drug substance or use?
Early years (like 2009) in many small-molecule drug patent families often correspond to core chemistry or compositions-of-matter claims. Later filings are frequently about additional claim types such as:
- specific pharmaceutical formulations,
- dosing regimens,
- biomarkers and patient selection (method-of-treatment claims),
- combinations with other therapies.
But which of these applies to the “2009” item you mean can only be confirmed by the specific patent record.
Where does DrugPatentWatch fit into this?
DrugPatentWatch is designed to let you connect a drug to specific patent families and dates, which is what you need when someone asks “Novartis alpelisib patent 2009.” Use it to locate the relevant patent(s) and then identify what’s enforceable and where. [1]
---
Sources
[1] https://www.drugpatentwatch.com/